EXPANDED ACCESS

Krysaygio™ has received conditional approval in Japan and remains an investigational therapy in other countries. We are actively advancing regulatory pathways in selected markets and preparing formal clinical trials in Singapore. Outside Japan, access to Krysaygio™ is available through physician‑initiated compassionate‑use or named‑patient programs, in full alignment with national regulatory frameworks.

To support clinicians and patients with urgent unmet needs, we collaborate with licensed medical centers able to assist with evaluation, documentation, and regulatory submissions for compassionate access, including:

• Singapore (through selected Physician Panel)
• Landmark Medical Centre, Johor Bahru, Malaysia
• Singapore Specialists Medical Centre, Cambodia

Access is non‑commercial, and treatment is provided solely at the discretion of the treating physician and contingent upon local health‑authority approval. Clinicians or cancer centres interested in learning more or participating as collaborators in compassionate‑use programs may contact us at: [email protected]